Treatment of chronic hepatitis C with weekly administration of interferon-α

Toshio Morizane; Tatehiro Kagawa; Hidetsugu Saito; Ferdinand M. Guevara; Shingo Miyaguchi; Masaharu Tsuchiya

doi:10.1007/BF02779313

Treatment of chronic hepatitis C with weekly administration of interferon-α

Toshio Morizane, Tatehiro Kagawa, Hidetsugu Saito, Ferdinand M. Guevara, Shingo Miyaguchi, Masaharu Tsuchiya

School of Pharmacy

Research output: Contribution to journal › Article › peer-review

Abstract

To evaluate the efficacy of weekly administration of interferon (IFN)-α, we studied 23 anti-HCV positive patients with chronic hepatitis diagnosed by liver needle biopsy. Thirteen patients received weekly intramuscular injections of 6 MU human lymphoblastoid interferon (HLBI) for 24 weeks, and the other 10 patients were given no treatment. We examined liver-specific idiotype-bearing antibody (LSIA) in the patients' sera. This HLBI treatment was easily tolerated by all the treated patients. In the treated group serum alanine aminotransferase (ALT) level significantly decreased during HLBI treatment. Normalization of serum ALT level by the end of treatment was observed in 7/13 (54% ) of the treated patients but in 0% of the non-treated patients. Anti-HCV was detectable in all the patients during the treatment. Those who had high LSIA levels did not respond to HLBI treatment. These results demonstrate that weekly administration of IFN is sufficient to suppress disease activity in patients with chronic hepatitis C and that patients with high LSIA levels are unlikely to respond to IFN therapy.

Original language	English
Pages (from-to)	254-255
Number of pages	2
Journal	Gastroenterologia Japonica
Volume	26
Issue number	3 Supplement
DOIs	https://doi.org/10.1007/BF02779313
Publication status	Published - 1991 Jul 1

ASJC Scopus subject areas

Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF02779313

Cite this

@article{104d6f4f89774172a834bb4e2be40134,

title = "Treatment of chronic hepatitis C with weekly administration of interferon-α",

abstract = "To evaluate the efficacy of weekly administration of interferon (IFN)-α, we studied 23 anti-HCV positive patients with chronic hepatitis diagnosed by liver needle biopsy. Thirteen patients received weekly intramuscular injections of 6 MU human lymphoblastoid interferon (HLBI) for 24 weeks, and the other 10 patients were given no treatment. We examined liver-specific idiotype-bearing antibody (LSIA) in the patients' sera. This HLBI treatment was easily tolerated by all the treated patients. In the treated group serum alanine aminotransferase (ALT) level significantly decreased during HLBI treatment. Normalization of serum ALT level by the end of treatment was observed in 7/13 (54% ) of the treated patients but in 0% of the non-treated patients. Anti-HCV was detectable in all the patients during the treatment. Those who had high LSIA levels did not respond to HLBI treatment. These results demonstrate that weekly administration of IFN is sufficient to suppress disease activity in patients with chronic hepatitis C and that patients with high LSIA levels are unlikely to respond to IFN therapy.",

author = "Toshio Morizane and Tatehiro Kagawa and Hidetsugu Saito and Guevara, {Ferdinand M.} and Shingo Miyaguchi and Masaharu Tsuchiya",

year = "1991",

month = jul,

day = "1",

doi = "10.1007/BF02779313",

language = "English",

volume = "26",

pages = "254--255",

journal = "Journal of Gastroenterology",

issn = "0944-1174",

publisher = "Springer Japan",

number = "3 Supplement",

}

TY - JOUR

T1 - Treatment of chronic hepatitis C with weekly administration of interferon-α

AU - Morizane, Toshio

AU - Kagawa, Tatehiro

AU - Saito, Hidetsugu

AU - Guevara, Ferdinand M.

AU - Miyaguchi, Shingo

AU - Tsuchiya, Masaharu

PY - 1991/7/1

Y1 - 1991/7/1

N2 - To evaluate the efficacy of weekly administration of interferon (IFN)-α, we studied 23 anti-HCV positive patients with chronic hepatitis diagnosed by liver needle biopsy. Thirteen patients received weekly intramuscular injections of 6 MU human lymphoblastoid interferon (HLBI) for 24 weeks, and the other 10 patients were given no treatment. We examined liver-specific idiotype-bearing antibody (LSIA) in the patients' sera. This HLBI treatment was easily tolerated by all the treated patients. In the treated group serum alanine aminotransferase (ALT) level significantly decreased during HLBI treatment. Normalization of serum ALT level by the end of treatment was observed in 7/13 (54% ) of the treated patients but in 0% of the non-treated patients. Anti-HCV was detectable in all the patients during the treatment. Those who had high LSIA levels did not respond to HLBI treatment. These results demonstrate that weekly administration of IFN is sufficient to suppress disease activity in patients with chronic hepatitis C and that patients with high LSIA levels are unlikely to respond to IFN therapy.

AB - To evaluate the efficacy of weekly administration of interferon (IFN)-α, we studied 23 anti-HCV positive patients with chronic hepatitis diagnosed by liver needle biopsy. Thirteen patients received weekly intramuscular injections of 6 MU human lymphoblastoid interferon (HLBI) for 24 weeks, and the other 10 patients were given no treatment. We examined liver-specific idiotype-bearing antibody (LSIA) in the patients' sera. This HLBI treatment was easily tolerated by all the treated patients. In the treated group serum alanine aminotransferase (ALT) level significantly decreased during HLBI treatment. Normalization of serum ALT level by the end of treatment was observed in 7/13 (54% ) of the treated patients but in 0% of the non-treated patients. Anti-HCV was detectable in all the patients during the treatment. Those who had high LSIA levels did not respond to HLBI treatment. These results demonstrate that weekly administration of IFN is sufficient to suppress disease activity in patients with chronic hepatitis C and that patients with high LSIA levels are unlikely to respond to IFN therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025884650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025884650&partnerID=8YFLogxK

U2 - 10.1007/BF02779313

DO - 10.1007/BF02779313

M3 - Article

C2 - 1909275

AN - SCOPUS:0025884650

SN - 0944-1174

VL - 26

SP - 254

EP - 255

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

IS - 3 Supplement

ER -

Treatment of chronic hepatitis C with weekly administration of interferon-α

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this